|
Additional information was received, occurred while in use, patient details provided, the event is resolved, and patient received intravenous epoprostenol, ambrisentan, sildenafil , spirolactone, prochlorperazine maleate, lansoprazole, apixaban, carbocisteine, and codeine.No product was returned.The reported complaint could not be confirmed.If the product is returned this complaint will be reopened for further investigation.A device history record (dhr) review was conducted which indicated all inspections were completed and no issues were noted during manufacture.
|